Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec;53(1):410-415.
doi: 10.1007/s00259-025-07413-w. Epub 2025 Jun 24.

First-in-human PET neuroimaging of [18F]OXD-2314

Emily Murrell #  1   2   3 , Lucas Narciso #  1   2   3 , Kimberly L Desmond  1   2   3 , Caitlin Chow  1 , Anton Lindberg  1 , Armando Garcia  1 , Chester A Mathis  4 , Samuel Svensson  5 , Antonio P Strafella  6   7   8   9 , Neil Vasdev  10   11   12
Affiliations

First-in-human PET neuroimaging of [18F]OXD-2314

Emily Murrell et al. Eur J Nucl Med Mol Imaging. 2025 Dec.

Abstract

Purpose: This first-in-human positron emission tomography (PET) study evaluates [18F]OXD-2314, a radiopharmaceutical designed for imaging tau in non-Alzheimer's disease tauopathies.

Methods: Synthesis of [18F]OXD-2314 was automated using a commercial module and validated for human use. Dynamic PET imaging was performed in healthy control subjects (2 female, 2 male, ages 49-65 years). Kinetic modelling was performed from brain time-activity curves and radiometabolite-corrected arterial input functions to estimate total distribution volumes (VT) in each region of interest.

Results: [18F]OXD-2314 met all release criteria for human use. PET imaging revealed an initial whole brain peak of 2.3 standardized uptake value, followed by a steady washout. Distribution of radioactivity was uniform among brain regions (VT range: 2.21 ± 0.29 to 2.81 ± 0.43 mL/cm3).

Conclusions: [18F]OXD-2314 was successfully translated to first-in-human PET imaging. No adverse events were reported and PET imaging in patient populations of non-AD tauopathies is underway.

Keywords: Alzheimer’s disease; First-in-human; PET; Tau; [18F]OXD-2314.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval: This study was approved by the CAMH Research Ethics Board and was conducted in accordance with the Declaration of Helsinki ethical standards. Consent to participate: Participants provided written informed consent in compliance with the Tri-Council Policy Statement of Ethical Conduct for Research Involving Humans. Consent to publish: Not applicable. Competing interests: S.S. was an employee of Oxiant Discovery during the conduct of the reported study who may own or hold stock options in the company. N.V. is a co-founder of MedChem Imaging, Inc., which did not contribute support for this study. The authors declare no other competing interest.

Figures

Fig. 1
Fig. 1
A Blood-to-plasma ratio and B percent parent fraction over the PET scan time (n = 4) C Representative radiometabolite HPLC chromatograms from one participant for plasma samples collected at 2.5, 15, 60, and 110 min. D [18F]OXD-2314 TACs for the frontal lobe for the four participants included in this study, alongside 1- and 2-TCM fitted curves
Fig. 2
Fig. 2
Average [18F]OXD-2314 SUV images (n = 4) over time. Dynamic PET images were normalized to the MNI space and averaged over time intervals (upper-left corner)
Fig. 3
Fig. 3
Average VT images (n = 4) of [18F]OXD-2314. Voxelwise parametric maps were normalized to the MNI space
See this image and copyright information in PMC

References

    1. Wongso H, Harada R, Furumoto S. Current progress and future directions in non-Alzheimer’s disease tau PET tracers. ACS Chem Neurosci. 2025;16:111–27. 10.1021/acschemneuro.4c00319. - PubMed
    1. Chassé M, Vasdev N. PET in neurotherapeutic discovery and development. Neurotherapeutics. 2025;22:e00498. 10.1016/j.neurot.2024.e00498. - PMC - PubMed
    1. Mekala S, Wu Y, Li Y-M. Strategies of positron emission tomography (PET) tracer development for imaging of tau and α-synuclein in neurodegenerative disorders. RSC Med Chem. 2025. 10.1039/D4MD00576G. - PMC - PubMed
    1. Jie CVML, Treyer V, Schibli R, Mu L. Tauvid™: the first FDA-approved PET tracer for imaging tau pathology in Alzheimer’s disease. Pharmaceuticals. 2021;14. 10.3390/ph14020110. - PMC - PubMed
    1. Schönecker S, Palleis C, Franzmeier N, Katzdobler S, Ferschmann C, Schuster S, et al. Symptomatology in 4-repeat tauopathies is associated with data-driven topology of [18F]-PI-2620 tau-PET signal. Neuroimage Clin. 2023;38:103402. 10.1016/j.nicl.2023.103402 - PMC - PubMed

LinkOut - more resources